title: Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms.
abstract: This study examines the response to dexamethasone-doxorubicin-vincristine (DAV) therapy, followed by conditioning regimen and autologous stem cells transplantation (ASCT) in patients with multiple myeloma in relation with the presence of polymorphisms in genes involved in drug metabolism (GSTP1) and DNA synthesis (TYMS). GSTP1 G313G genotype (OR=5.49; 95% CI, 1.3-22.5, p=0.02) and TYMS A227A genotype (OR=3.41; 95% CI, 1.3-8.9, p=0.01) resulted significantly associated with a poor response following chemotherapy and the risk increased for the combined genotype (OR=13.54; 95% CI, 2.0-91.3, p=0.01). TYMS T157T genotype was significantly associated with a poor response after ASCT (OR=4.60; 95% CI, 1.2-16.9, p=0.02). Pre-therapeutic individual determination of the GSTP1 and TYMS polymorphisms could help in choosing the most appropriate protocol.
authors.affiliation: Department of Biology, Pisa University, Pisa, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Maggini
authors.forename: Gabriele
authors.initials: G
authors.lastname: Buda
authors.forename: Sara
authors.initials: S
authors.lastname: Galimberti
authors.forename: Elena
authors.initials: E
authors.lastname: Conidi
authors.forename: Nicola
authors.initials: N
authors.lastname: Giuliani
authors.forename: Fortunato
authors.initials: F
authors.lastname: Morabito
authors.forename: Giovenzio
authors.initials: G
authors.lastname: Genestreti
authors.forename: Pasquale
authors.initials: P
authors.lastname: Iacopino
authors.forename: Vittorio
authors.initials: V
authors.lastname: Rizzoli
authors.forename: Roberto
authors.initials: R
authors.lastname: Barale
authors.forename: Mario
authors.initials: M
authors.lastname: Petrini
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Rossi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D005260:Female; D051549:Glutathione S-Transferase pi / Q000235:genetics*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000628:therapy*; D015376:Nimustine / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013940:Thymidylate Synthase / Q000235:genetics*; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D015376:Nimustine; D014750:Vincristine; D003606:Dacarbazine; D003520:Cyclophosphamide; D013940:Thymidylate Synthase; D051549:Glutathione S-Transferase pi; D008558:Melphalan